Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al
Scientific publications describe BPC-157 within preclinical or experimental research environments
Then again, allowing American companies to sell BPC-157 for human use could create the impression that the peptide, which hasnt passed through the rigorous process the FDA uses to approve new drugs, nonetheless has the agencys blessing
15.2.10 STRUCTURE THERAPEUTICS, INC
AOD 9604: Chemical Identity AOD 9604 is a synthetic growth hormonederived peptide fragment corresponding to the C-terminal lipolytic region of human GH, with an additional N-terminal tyrosine residue incorporated to improve structural stability in laboratory systems
Continuing peptide use while ignoring worsening symptoms is medically inappropriate.